Adaptimmune Therapeutics plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Adaptimmune Therapeutics plc
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
The UK’s biotech sector sees investor interest surge during the pandemic, though IPO levels are still disappointing compared with recent years.
Deal Snapshot: Set to begin a Phase II study that Alpine will complete, ALPN-101 is a dual inhibitor of CD28 and ICOS that may offer a new treatment option in SLE.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Adaptimmune LLC
- Adaptimmune Ltd.